cystic fibrosis

Hubrecht Organoid Technology (HUB) and the Dutch health insurance companies CZ, Zilveren Kruis and Menzis plan to launch a €3 million ($3.1 million) validation trial to determine whether HUB’s organoid technology can be used to assess how cystic fibrosis (CF) patients might respond to new therapies. HUB’s technology is based…

Protalix BioTherapeutics’ AIR DNase (alidornase alfa), developed to make mucus in the lungs of cystic fibrosis (CF) patients less sticky, showed remarkably good results in an early analysis of a small, proof-of-concept Phase 2 trial (NCT02722122). The inhaled drug is a DNase, an enzyme that works to chop…

A number of important discoveries, therapeutic developments, and events related to cystic fibrosis (CF) were reported daily by Cystic Fibrosis News Today throughout 2016. Now that the year is over, it is time to briefly review the articles that appealed most to our readers. Here are the top 10 most-read…

The bacteria Pseudomonas aeruginosa, which settle in the lungs of most cystic fibrosis (CF) patients, destroy the lungs by perpetuating the inflammation that aims to control invading microbes, according to a study. This contra-intuitive finding demonstrates the power of the mechanisms bacteria use to gain a survival advantage. It also…

In a small randomized clinical trial, researchers at Karolinska Institute in Sweden showed that vitamin D supplements may improve lung function in cystic fibrosis (CF) patients. A daily intake of high levels of vitamin D are required, however, for the effects to be noticed. The study, “Clinical…

Under a research contract award granted by the Cystic Fibrosis Foundation Therapeutics (CFFT), Matinas BioPharma and the Colorado State University (CSU) will jointly conduct preclinical studies assessing the efficacy of MAT2501, a potential oral antibiotic, in treating nontuberculous mycobacterium infection (NTM) in a cystic fibrosis (CF) lung model.

Measuring antibodies in the blood and administering lung-function tests, either alone or in combination, significantly increase health-care specialists’ ability to detect the serious bacteria Pseudomonas aeruginosa in children with cystic fibrosis (CF). The study, “Assessment of serology and spirometry and the combination of both to complement microbiological isolation…

Researchers at the University of Limerick, in Ireland, have developed a disposable percussion device, called SoloPEP, that works to remove mucus from the airways of people with cystic fibrosis (CF) so as to lessen their likelihood of infections, leading  to fewer doctor’s appointments, less antibiotic use, and shorter hospital stays. “SoloPEP…

Researchers at the University of Pittsburgh have been awarded with a $1.7 million grant from the National Institutes of Health (NIH) to develop better ways of evaluating, and potentially treating, cystic fibrosis (CF). Specifically, the grant will be used to develop mathematical models of liquid and ion transport in the human…

A research team at Northwestern University has developed a flexible and wearable electronic device, which adheres to the skin, to measure sweat, monitor response to exercise, and detect the presence of certain biomarkers — all of which are relevant for conditions such as cystic fibrosis (CF). “Sweat is a rich, chemical…